Manzamine A: A promising marine-derived cancer therapeutic for multi-targeted interactions with E2F8, SIX1, AR, GSK-3β, and V-ATPase - A systematic review

作     者：Mishan, Mohammad Amir Choo, Yeun-Mun Winkler, Jeffery Hamann, Mark T. Karan, Dev 

作者机构：Brown Canc Ctr Dept Urol 505 S Hancock St Louisville KY 40202 USA Univ Malaya Fac Sci Dept Chem Kuala Lumpur 50603 Malaysia Univ Penn Dept Chem Philadelphia PA USA Med Univ South Carolina Coll Pharm Dept Drug Discovery & Biomed Sci & Publ Hlth Charleston SC USA Med Univ South Carolina Coll Med Hollings Canc Ctr Charleston SC USA 

出 版 物：《EUROPEAN JOURNAL OF PHARMACOLOGY》 (Eur. J. Pharmacol.)

年 卷 期：2025年第990卷

页      面：177295页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 10[医学] 

主　　题：Manzamine A SIX1 AR GSK-3 beta V-ATPases Cell cycle regulation Cancer therapy 

摘      要：Manzamine A, a natural compound derived from various sponge genera, features a beta-carboline structure and exhibits a range of biological activities, including anti-inflammatory and antimalarial effects. Its potential as an anticancer agent has been explored in several tumor models, both in vitro and in vivo, showing effects through mechanisms such as cytotoxicity, regulation of the cell cycle, inhibition of cell migration, epithelial-tomesenchymal transition (EMT), autophagy, and apoptosis through multi-target interactions of E2F transcriptional factors, ribosomal S6 kinases, androgen receptor (AR), SIX1, GSK-3 beta, v-ATPase, and p53/p21/p27 cascades. This systematic review evaluates existing literature on the potential application of this marine alkaloid as a novel cancer therapy, highlighting its promising ability to inhibit cancer cell growth while causing minimal side effects.